{"entity":{"id":"nct05658562","kind":"trial","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","aka":[],"tldr":"A phase 1/2 trial of Loncastuximab tesirine in diffuse large b-cell lymphoma, run by Tanabe Pharma Corporation, active and no longer recruiting.","summary":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL is a phase 1/2 interventional study registered as NCT05658562 by Tanabe Pharma Corporation, with 46 participants enrolled, started 2023-01-30 and due to reach its primary completion in 2028-08. Interventions recorded: MT-2111. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05658562","url":"https://clinicaltrials.gov/study/NCT05658562"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["zynlonta"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05658562","phase":"1/2","setting":"A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","sponsor":"Tanabe Pharma Corporation","enrolled":46,"outcomes":[]},"route":"/trials/nct05658562/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/"}]}}